Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulbactam-Durlobactam vs Colistin in Acinetobacter Infections
NCT03894046Phase 3Completed
- Sponsor
- Entasis Therapeutics
- Start
- Sep 2019
- Primary completion
- Jul 2021
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 17
01
Overview
A Phase 3 trial of durlobactam in Acinetobacter baumannii infection, hospital-acquired bacterial pneumonia (HAP), ventilator-associated pneumonia (VAP), Bacteremia, sponsored by Entasis Therapeutics. Started Sep 2019; status: completed.
02
Drugs
durlobactam
03
Conditions
Acinetobacter baumannii infectionhospital-acquired bacterial pneumonia (HAP)ventilator-associated pneumonia (VAP)Bacteremia
Beyond the preview
Go deeper on NCT03894046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03894046.